British American Tobacco (BAT) says it is focussing on the science as it conducts the “first real-world study assessing the impact of Vuse on indicators for several smoking-related diseases”.
It says the results will provide “a first-of-its kind dataset – adding to the substantial amounts of scientific evidence generated about Vuse”.
BAT says this demonstrates its focus on science and innovation to deliver “A Better Tomorrow” and reduce the health impact of its business.
BAT says it has conducted a first-of-its-kind study of Vuse designed to assess and provide insights into the real-world health impact of vaping. The study compares biomarker measures from Vuse consumers who have been using the product for over six months with the results from smokers, former smokers and never smokers. Protocol details explaining the innovative design of the latest study were published in the Journal of Health and Environmental Research.
Dave Cross – Planet of the Vapes – 2022-06-17.
Want More Investigative Content?
